EUVIMEDEUVIMED entdecken
EditorialOpen Access · CC BY-NC 3.0

Psychedelics and Ibogaine “Pain Medications” at the Pharmacy Counter: Implications for Pharmacy Practice

Frank Breve, Frank J Berenato, Joseph V Pergolizzi, Giustino Varrassi iD, Robert B Raffa iD

Journal of Pain Research · 2026-07 · Volume 19 · 1-4

DOI: 10.2147/jpr.s629049 ↗

Kurz gefasst

Editorial in der Zeitschrift Journal of Pain Research, 2026-07. Verfasst von Frank Breve und 4 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy, Mid Atlantic PharmaTech Consultants, Ventnor City, NJ, USA. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The regulatory process governing psychedelic substances in the United States is undergoing its most significant transformation since the Controlled Substances Act of 1970. An executive order signed in April 2026 directed federal agencies to accelerate development pathways for psychedelic and related therapies. These developments signal that FDA approval of one or more psychedelic agents is no longer a distant prospect, but a foreseeable regulatory event. Since there is a growing interest and some evidence for psychedelics and ibogaine for treatment of pain (though the field is at different stages of maturity for different compounds and pain types), the executive order will affect pain research and practice. The directive is an acknowledgement that the pharmacological landscape of psychiatric and addiction medicine is being reshaped by converging forces: a deepening mental health crisis, inadequate response rates to conventional pharmacotherapy in conditions such as treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and a growing body of clinical trial evidence supporting the efficacy of psychedelic-assisted therapies. 1–3 The executive order hopes to compress standard review timelines from about six to ten months to about sixty days. 4 Approval of psychedelic-assisted therapies (Table 1) will require substantial evolution of pharmacy practice across multiple domains: Controlled Substance Act (CSA) scheduling and controlled substance management, Risk Evaluation and Mitigation Strategy (REMS) program administration, pharmacogenomic screening, drug interaction counseling, patient education, and integration

Autor:innen und Institutionen

  • Clinical Pharmacy, Mid Atlantic PharmaTech Consultants, Ventnor City, NJ, USA.
  • Compounding, Med Shoppe, Philadelphia, PA, USA.
  • Research and Development, Enalare Therapeutics, Mullica Hill, NJ, USA.
  • Anesthesiology, NEMA Research, Naples, FL, USA.
  • VIBRA Research Group, Fondazione Paolo Procacci, Roma, Italy.
  • School of Pharmacy, Temple University (Emeritus), Philadelphia, PA, USA.

ORCID-Profile: Giustino Varrassi, Robert B Raffa

Zitieren

APA

Breve, F., Berenato, F. J., Pergolizzi, J. V., Varrassi, G., & Raffa, R. B. (2026). Psychedelics and Ibogaine “Pain Medications” at the Pharmacy Counter: Implications for Pharmacy Practice. Journal of Pain Research, Volume 19, 1-4. https://doi.org/10.2147/jpr.s629049

Vancouver

Breve F, Berenato FJ, Pergolizzi JV, Varrassi G, Raffa RB. Psychedelics and Ibogaine “Pain Medications” at the Pharmacy Counter: Implications for Pharmacy Practice. Journal of Pain Research. 2026;Volume 19:1-4. doi:10.2147/jpr.s629049

BibTeX
@article{Breve2026,
  author = {Breve, Frank and Berenato, Frank J and Pergolizzi, Joseph V and Varrassi, Giustino and Raffa, Robert B},
  title = {Psychedelics and Ibogaine “Pain Medications” at the Pharmacy Counter: Implications for Pharmacy Practice},
  journal = {Journal of Pain Research},
  year = {2026},
  volume = {Volume 19},
  pages = {1--4},
  doi = {10.2147/jpr.s629049}
}
Kostenlos starten →